CKPT Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -87.96%. Checkpoint Therapeutics's return on equity of -- beat Fortress Biotech's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 5.69%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 834.96%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Checkpoint Therapeutics's net income of -$9.7M is higher than Fortress Biotech's net income of -$12.9M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 0.46x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of -34.09%. Checkpoint Therapeutics's return on equity of -- beat Quanterix's return on equity of -11.35%.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 5.69%. On the other hand Quanterix has an analysts' consensus of $13.13 which suggests that it could grow by 123.21%. Given that Quanterix has higher upside potential than Checkpoint Therapeutics, analysts believe Quanterix is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Quanterix has a beta of 1.351, suggesting its more volatile than the S&P 500 by 35.098%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Quanterix quarterly revenues of $34.1M. Checkpoint Therapeutics's net income of -$9.7M is higher than Quanterix's net income of -$11.6M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.67x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of 24.9%. Checkpoint Therapeutics's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 5.69%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.67 which suggests that it could grow by 74.62%. Given that Rigel Pharmaceuticals has higher upside potential than Checkpoint Therapeutics, analysts believe Rigel Pharmaceuticals is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.928%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are smaller than Rigel Pharmaceuticals quarterly revenues of $57.6M. Checkpoint Therapeutics's net income of -$9.7M is lower than Rigel Pharmaceuticals's net income of $14.3M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 20.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus 1.90x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of -16268.29% compared to Checkpoint Therapeutics's net margin of --. Checkpoint Therapeutics's return on equity of -- beat Trevi Therapeutics's return on equity of --.

Checkpoint Therapeutics has a consensus price target of $4.33, signalling upside risk potential of 5.69%. On the other hand Trevi Therapeutics has an analysts' consensus of $19.83 which suggests that it could grow by 206.54%. Given that Trevi Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Trevi Therapeutics is more attractive than Checkpoint Therapeutics.

Checkpoint Therapeutics has a beta of 1.211, which suggesting that the stock is 21.135% more volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.406, suggesting its less volatile than the S&P 500 by 59.351%.

Checkpoint Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Checkpoint Therapeutics pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Checkpoint Therapeutics quarterly revenues are $41K, which are larger than Trevi Therapeutics quarterly revenues of --. Checkpoint Therapeutics's net income of -$9.7M is higher than Trevi Therapeutics's net income of -$11.4M. Notably, Checkpoint Therapeutics's price-to-earnings ratio is -- while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Checkpoint Therapeutics is -- versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.